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Purpose: The aim of this study was to compare the antiinﬂammatory
effect and ocular surface toxicity of topical nonpreserved methylpred-
nisolone sodium succinate 1% and preserved prednisolone acetate
suspension 1% for the management of acute anterior uveitis (AAU).
Methods: In this prospective, randomized, investigator-masked,
comparative clinical trial, patients with mild-to-moderate noninfectious
AAU were assigned randomly to receive either hourly nonpreserved
methylprednisolone 1% (group A) or preserved prednisolone 1%
(group B) eye drops followed by a 2-week tapering regimen. Anterior
chamber cells and ﬂare were clinically evaluated for the objective
comparison of the antiinﬂammatory effect. The main outcome measure
was the percentage of patients with a resolution of inﬂammation
(anterior chamber cells ,1+) on day 14. Ocular surface toxicity was
assessed by means of the corneal ﬂuorescein staining score, tear
breakup time, Schirmer I test, and questionnaire-based grading of ocu-
lar discomfort parameters.
Results: Seventy-two eyes of 68 patients were studied, of which
38 eyes were enrolled in group A and 34 eyes were enrolled in
group B. On day 14, 76.3% of the patients in group A had resolution
of inﬂammation compared with 70.6% of the patients in group B,
proving noninferiority (x2 = 0.303, P = 0.582). The mean anterior
chamber cell grade reduction for patients in group A was similar to
that in group B (2.52 vs. 2.86, respectively; P = 0.92). Group A
patients showed signiﬁcantly lower corneal ﬂuorescein staining scores
(P, 0.001) and reported milder subjective ocular discomfort (0.55 vs.
1.43, P = 0.01) as compared with group B.
Conclusions: Both preparations demonstrated equal antiinﬂammatory
effects for the treatment of AAU. Nonpreserved methylprednisolone
eye drops exhibited a signiﬁcantly lower ocular surface toxicity proﬁle
and milder subjective discomfort when compared with that exhibited
by preserved prednisolone.
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Topical steroids are the standard treatment for noninfec-tious acute anterior uveitis (AAU). Current clinical prac-
tice emphasizes aggressive treatment to bring uveitis under
control as rapidly as possible. With frequent topical eye drop
instillation, ocular surface epitheliopathy related to preser-
vatives in topical ophthalmic preparations is a major concern.
The toxic action of preservatives on the ocular surface has
been widely demonstrated in vitro and in vivo, in both hu-
mans and animals.1 Besides, it was shown that the frequency of
symptoms and objective signs of ocular surface irritation was
higher with preserved eye drops than with preservative-free
eye drops.2 For the treatment to be effective, side effects need
to be minimized to promote compliance and allow continuation
of therapy.
Topical nonpreserved methylprednisolone has been
used successfully to treat keratoconjunctivitis sicca associated
with Sjögren syndrome.3 As a nonpreserved preparation, it is
proven to be a safe and effective treatment to improve sub-
jective and objective dry eye factors in Sjögren syndrome.4
Based on its well-documented, antiinﬂammatory, and safety
proﬁle, we conducted this study to evaluate the efﬁcacy of
this nonpreserved steroid preparation to treat AAU and com-
pare its antiinﬂammatory and ocular surface toxicity with that
of commercially available prednisolone acetate suspension
1%, which was used in several large clinical trials, as the
comparator arm.5–7
MATERIALS AND METHODS
This prospective, randomized, investigator-masked,
comparative clinical study was conducted from November
2011 to February 2013 at the Noor Eye Hospital, Tehran. The
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study protocol was approved and registered by the Iranian
Registry of Clinical Trials (IRCT2012101511125N1) in accor-
dance with the International Clinical Trials Registry Platform,
which complied with the Declaration of Helsinki. Written
informed consents were obtained from all the patients before
enrollment in the study.
Patients with unilateral AAU and at least 2+ anterior
chamber cells based on the Standardization of Uveitis
Nomenclature (SUN) Working Group Classiﬁcation were
assigned randomly to receive either hourly nonpreserved
methylprednisolone sodium succinate 1% (group A) or pre-
served prednisolone acetate 1% (group B) followed by a
2-week tapering regimen.8 Eligibility criteria were age
16 years or older, attack duration less than a 1-week period,
intraocular pressure (IOP) #21 mm Hg at presentation, and
negative evidence for infectious (eg, corneal scars, iris atro-
phy) or granulomatous (eg, granulomatous keratic precipitate
or iris nodule) inﬂammation. The following exclusion criteria
were used: eyes with hypopyon or ﬂorid ﬁbrin formation,
previous unsuccessful topical treatment, known cases of
Behçet disease, cases with evidence for the other causes
attributable to their uveitis (eg, positive skin tuberculin test),
any slit-lamp evidence of signiﬁcant blepharitis or meibomian
gland dysfunction, concomitant topical eye drops for chronic
eye disease (eg, glaucoma medication, artiﬁcial tear), and the
recent use of contact lenses.
At presentation, a detailed history of recent illness
along with the course, treatment, and outcome of previous
attack(s) was taken. Known cases of “idiopathic” or “HLA
B27-related” anterior uveitis that had experienced previous
attack(s) were treated without further investigation. New
cases with typical nongranulomatous AAU were checked on-
ly for HLA B27 positivity. Atypical cases underwent further
investigation and were excluded, if positive clues for other
attributable causes were found (eg, positive skin tuberculin
test). Ocular examination, including a dilated fundus exami-
nation, was performed in a semidark room to classify the
anatomic location and histopathologic type of inﬂammation.
If the media opacity obscured funduscopy, B-scan ultrasonog-
raphy assisted the clinician to rule out vitreous involvement.
Optical coherence tomography was obtained when macular
edema was suspected. Ocular inﬂammatory parameters (anterior
chamber cell and ﬂare) and corneal toxicity and tear ﬁlm sta-
bility indices [corneal ﬂuorescein staining scores, ﬂuorescein
tear breakup time (TBUT), and Schirmer I test] were deter-
mined. The IOP was measured by Goldman applanation tonom-
etry at the end of the examination. At each follow-up visit
(weeks 1 and 2), in addition to the above-mentioned examina-
tion and measurement, a questionnaire-based grading system
was used to evaluate the amount of subjective discomfort expe-
rienced by patient. The questionnaire is in the following section
named “measurements of subjective ocular discomfort.”
Randomization and Study Medications
In this prospective, randomized, investigator-masked,
comparative study, the eyes of qualiﬁed patients were
assigned in a 1:1 ratio to 1 of the treatment groups using
the balanced blocked randomization method. The study
medications were nonpreserved methylprednisolone sodium
succinate 1% (group A) or preserved prednisolone acetate
suspension 1% (group B). The preserved prednisolone (Pred
Forte 1%, Allergan, Inc) eye drops contain benzalkonium
chloride (BAC) 0.004%. A topical solution of nonpreserved
methylprednisolone was prepared by the Laboratory of the
Noor Eye Hospital by diluting intravenous methylpredniso-
lone sodium succinate in sterile balanced salt solution to ﬁnal
concentrations of 1%. The process was performed under clean
conditions of a laminar hood, and the solution was ﬁltered
through a 0.2-mm cellulose acetate ﬁlter papers. The patients
were dispensed bottles containing 10 mL of the steroid solu-
tion and were asked to keep these refrigerated and to discard
these after 4 weeks. The patients were instructed to instil 1
drop of study medications hourly in the affected eyes for the
ﬁrst 72 hours and then every 2 hours for the rest of the week.
During sleep time, betamethasone 0.1% topical ointment
(Betamethasone, preservative: BAC 0.004%; Sina-Darou
Pharmaceutical Co, Tehran, Iran) was applied instead of eye
drops. Homatropine 2% eye drops (Homydrin, preservative:
BAC 0.004%; Sina-Darou Pharmaceutical Co) were pre-
scribed for all the patients every 8 hours. The patients were
instructed to come back to the clinic immediately if their
symptoms aggravated. Except for the coordinator distributing
the study medications, all the investigators remained blinded
to the allocation throughout the entire study. The participants
were not masked because of ethical and feasibility constraints.
At the ﬁrst-week follow-up visit, the patients who did
not improve clinically (at least a 2-step reduction of anterior
chamber cell grade) were considered “refractory to topical
treatment,” and an additional regional steroid injection or oral
prednisolone was given to them. The refractory to topical
treatment cases were considered as part of treatment failure
and were treated by preserved prednisolone eye drops for the
rest of the study. Patients with a good response in the ﬁrst
week of treatment were encouraged to continue the eye drops
in a tapering regimen according to clinical response. All the
patients were visited again 2 weeks after the treatment to
evaluate the success of the treatment. Successful treatment
was deﬁned as aqueous cells equal or less than grade 1.
Treatment failure includes cases that did not fulﬁll the 2-week
endpoint goal together with refractory to topical treatment
cases.
Measurements of Inflammatory Parameters
Anterior Chamber Cell
The intensity of the cellular reaction in the anterior
chamber was assessed based on the number of inﬂammatory
cells seen in a 1- · 1-mm full intensity beam at 45 to 60
degrees and were graded according to the SUN Working
Group Classiﬁcation.
Anterior Chamber Flare
Anterior chamber ﬂare was assessed using the laser
ﬂare photometer (FM-600; Kowa, Tokyo, Japan). Seven
consecutive laser ﬂare readings at the lower third of the
anterior chamber were obtained, with a background scatter
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of ,20%. The highest and lowest readings were discarded,
and the remaining 5 were averaged to obtain the ﬂare
measurement.
Measurements of Corneal Toxicity and Tear
Film Stability Indices
Fluorescein Tear Breakup Time
The ﬂuorescein TBUT was measured as follows: 2 mL
of ﬂuorescein solution 1% was instilled in a lower cul-de-sac
using a micropipette. The patient was instructed to blink
several times to distribute the ﬂuorescein evenly on the cor-
neal surface. The patient was then asked to stare directly
ahead without blinking. The tear ﬁlm was examined under
blue light illumination of a biomicroscope, and any breakup
of the tear ﬁlm was noted. A digital timer recorded the time
from the blink until a dark spot appeared in the tear ﬂuores-
cein layer.
Corneal Fluorescein Staining Scores
After the instillation of ﬂuorescein solution and mea-
surement of TBUT, corneal ﬂuorescein staining was scored
according to the protocol described by Shimmura et al.9 The
cornea was divided into 3 equal areas of upper, middle, and
inferior compartments and examined by means of a slit lamp
using blue light illumination. Based on the number and extent
of punctate epithelial erosions visible, each compartment was
graded on a scale of 0 (no staining) to 3 points (intense
staining) with a maximum staining score of 9 points for each
cornea examined.
Schirmer I Test
Tear production was determined by the Schirmer I test.
The Schirmer test was performed after corneal staining,
because it may affect the staining pattern of the cornea with
ﬂuorescein. The eye was anesthetized by instilling 1 drop of
tetracaine hydrochloride 0.5% (Anestocaine 0.5%, preserva-
tive: BAC 0.004%; Sina-Darou Pharm Co). A standard ﬁlter
paper strip was placed inside the margin of the inferolateral
third of the lower eyelid, taking care to prevent the paper from
contacting the cornea. After 5 minutes, the level of strip
wetting (in millimeters) was measured.
Measurements of Subjective
Ocular Discomfort
This parameter was evaluated before the slit-lamp
examination and consisted of questioning about (1)
discomfort or pain upon the instillation of eye drops; (2)
stinging or burning sensation between instillations of eye
drops; (3) foreign body or gritty sensation; and (4) tearing.
Each parameter was scored by the patient as follows: 0,
absent; 1, mild; 2, moderate (patient continued using eye
drops); and 3, intolerable (the patient stopped using
eye drops). Subjective discomfort score was determined
by the summation of the scores given to each question
(min = 0, max = 12).
Safety Parameter
The IOP was measured as the last step in the examina-
tion using applanation tonometry, and the values were recorded
in millimeters of mercury.
Statistical Analysis
Quantitative variables were expressed as the mean,
standard deviation, and conﬁdence interval. Statistical testing
of the noninferiority hypothesis was based on 95% conﬁdence
intervals on the parameter of interest. The repeated measures
analysis of variance was used to check quantitative variables
for changes over time. The independent sample t test was
used for testing quantitative variables, and the x2 test was
applied for qualitative variables. P , 0.05 was considered
statistically signiﬁcant.
RESULTS
Of the 78 eligible eyes (74 patients) enrolled, 40 and
38 eyes were randomly assigned to the preservative-free
methylprednisolone (group A) and preserved prednisolone
(group B) treatment groups, respectively. Two patients in
group A and 4 in the group B did not complete the study because
of protocol violation or were lost to follow-up (Fig. 1). The
demographic proﬁle of the patients is shown in Table 1.
In the ﬁrst week of follow-up, 7 of 38 cases in group A
(18.4%) and 6 of 34 patients (17.6%) in group B were
withdrawn because the investigator determined that the
patients were refractory to topical treatment (anterior chamber
cell grade improvement was less than a 2-step reduction), and
an additional regional steroid injection or oral prednisolone
was required for them (x2 = 0.007, P = 0.932). At the second-
week follow-up visit, 29 of the 38 patients (76.3%) in group A
and 24 of the 34 patients (70.6%) in group B had an anterior
chamber cell grade equal or less than grade 1 (x2 = 0.303, P =
0.582). This proves noninferiority of methylprednisolone ther-
apy for achieving a resolution of inﬂammation as the endpoint
goal in this study.
Measurements of Inflammatory Parameter
Anterior Chamber Cells
For the individual treatment groups, there was a signif-
icant reduction of the mean anterior chamber cell grades from
baseline to the ﬁrst and second follow-up weeks (Fig. 2).
Mean anterior chamber cell grades were not signiﬁcantly dif-
ferent between the 2 groups (P = 0.60 and P = 0.88; at the
ﬁrst- and second-week follow-up visits, respectively). On day
14, the mean anterior chamber cell grade improvement for
group A was similar to that for group B (2.52 vs. 2.86,
respectively; P = 0.092), proving noninferiority.
Anterior Chamber Flare
The reduction in ﬂare values on day 14 was comparable
between groups A and B (188.4 vs. 240.1 respectively; P =
0.141). At baseline and during the follow-up, there was no
signiﬁcant difference between the treatment groups concern-
ing mean ﬂare values (P = 0.19, P = 0.60, and P = 0.56 at
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baseline and at the ﬁrst and second weeks, respectively).
Within individual groups, the ﬂare values showed a signiﬁcant
decrease at each follow-up visit (Fig. 2).
Measurements of Corneal Toxicity and Tear
Film Stability Indices
Corneal Fluorescein Staining Scores
Before treatment, the ﬂuorescein staining score was not
different between the 2 groups (1.38 vs.1.29, P = 0.82). The
scores remained relatively stable in group A, whereas these
increased in group B over follow-up time (Fig. 3). The pre-
served prednisolone group showed signiﬁcantly higher values
in posttreatment visits compared with the nonpreserved meth-
ylprednisolone group (1.67 vs. 2.65, P = 0.02 and 1.81 vs. 3.54,
P , 0.001 at 1 and 2 weeks, respectively).
Schirmer I Test
The Schirmer strip wetting length (in millimeters)
decreased in the ﬁrst and second follow-up times in both
the groups (Fig. 4). The Schirmer score was not different at
baseline and posttreatment visits between the 2 treatment
groups (P = 0.64, P = 0.12, and P = 0.93 at baseline and at
the ﬁrst and second weeks, respectively).
Fluorescein TBUT
The subjects in both the groups had a higher mean
ﬂuorescein TBUT at pretreatment compared with that at the
ﬁrst and second posttreatment visits, but the difference was
not statistically signiﬁcant (Fig. 4). Between groups, the mean
ﬂuorescein TBUT was not different at baseline or at the fol-
low-up visit (P = 0.22, P = 0.50, and P = 0.65 at baseline and
at the ﬁrst and second weeks, respectively).
Measurements of Subjective
Ocular Discomfort
In the group of subjects receiving preservative-free
methylprednisolone, the scores for subjective discomfort
decreased, whereas the subjects using preserved prednisolone
eye drops experienced increased scores from the ﬁrst to the
second week of the follow-up (Fig. 3). At the second-week
follow-up visit, preservative-free methylprednisolone-treated
patients reported a signiﬁcantly lower subjective discomfort
compared with that of the control group (0.55 vs.1.43, P = 0.01).
FIGURE 1. Randomization and allocation schema and treatment outcome in group A (nonpreserved methylprednisolone) and in
group B (preserved prednisolone).
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Safety Parameters
Intraocular Pressure
The IOP of the 2 patients in group A and 1 patient in
group B started rising during the ﬁrst 2 weeks of treatment but
did not exceed 21 mm Hg, and none of them required
antiglaucoma medication. The difference in the IOP was not
signiﬁcant between groups A and B at the follow-up visits
(Fig. 5).
DISCUSSION
In humans, interesting experimental studies have shown
deleterious effects of preservatives after the use of antiglau-
coma preserved eye drops, but there are few studies, if any, to
compare preserved and unpreserved steroid solutions for the
treatment of anterior uveitis.10–12 Our preliminary experience
with the successful use of nonpreserved topical methylpred-
nisolone for the treatment of noninfectious anterior uveitis
encouraged us to conduct this study to evaluate and compare
its antiinﬂammatory effect and ocular surface toxicity proﬁle
with prednisolone acetate suspension 1% as the standard care
for AAU.
In our study, nonpreserved methylprednisolone 1% was
found to be noninferior to prednisolone acetate 1% for the
treatment of noninfectious AAU with comparable results for
multiple objective efﬁcacy endpoints. On the basis of an
analysis of the means, the results for patients on methylpred-
nisolone were equivalent to those on prednisolone acetate at
the same dosing frequency.
The preserved prednisolone eye drops used in our study
contain BAC, a quaternary ammonium compound that is the
most commonly used preservative in topical ophthalmic
preparations. BAC has been demonstrated to have adverse
effects on the cornea and conjunctiva.1,13 Three mechanisms
of BAC toxicity have been described: a detergent effect, caus-
ing loss of tear ﬁlm stability; direct damage to the corneal and
conjunctival epithelium; and immunoallergic reaction.13
Our results showed that corneal ﬂuorescein staining
scores, which reﬂect the extent of punctuate epithelial erosion,
were signiﬁcantly lower in the preservative-free methylpred-
nisolone group than in the control group. However, patients
treated with preservative-free eye drops experienced less
subjective discomfort during the follow-up examination when
compared with preserved prednisolone. In fact, a steady
increase in the corneal ﬂuorescein staining and subjective
discomfort scores was found when applying the preservative
eye drops, but this was only minimal for the preservative-free
eye drops.
FIGURE 2. Mean anterior chamber cell (left) and flare (right) with the corresponding error bar depicting the 95%
confidence interval before the treatment and 1 and 2 weeks after the treatment in groups A and B. ph/ms, photons per
millisecond.
TABLE 1. Patient Demographics and Clinical Profiles at





Mean age (range), yrs 41.2 (16–63) 36.4 (20–52)
Gender
Male, % 78.9 70.6
Total number of episodes (mean) 2.4 3.6
Interval between the beginning of
the attack and entering into the
study (mean days)
4.7 4.4
Days received topical medication
before entering into the study
(mean)
2.1 1.9
Percent of HLA27 positivity, % 18.4 29.4
Baseline inﬂammatory parameter
Mean anterior chamber ﬂare,
ph/ms
210.8 267.2
Mean anterior chamber cells 3.38 3.65





Fluorescein TBUT (mean), s 17.5 16.2
Schirmer strip wetting length
(mean), mm
14.4 13.2
Mean baseline IOP 6 SD, mm Hg 11.7 6 3.3 11.1 6 3.9
ph/ms, photons per millisecond.
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In addition to the induction of punctuate epithelial
erosion, the reduction in tear production and shortening of the
TBUT are other parameters that could potentially reﬂect the
toxic effects of BAC on the ocular surface.14–16 In our study,
the shortening of the TBUT did not show statistically signif-
icant differences between the preservative and preservative-free
medication groups. This fact could be explained by a short
period of treatment, which was probably not long enough for
the preservative to induce measurable changes on tear
structure.
Basic tear production (as measured by the Schirmer
test) was not different in the preservative and preservative-
free groups as well. Tearing during the acute stage of
inﬂammation may play a confounding role for the assessment
of the amount of basic tear production. It was expected that by
a resolution of inﬂammation, the amount of tearing would
decrease, which was shown by a signiﬁcantly shorter
length of the Schirmer strip wetting in the ﬁrst and second
weeks compared with that in the pretreatment state in both
groups.
Pﬂugfelder et al reported that only 1 of their 21 patients
receiving topical nonpreserved methylprednisolone had an
increased IOP at 3 months while treating their dry eye
condition. Although the patients in our study received a more
frequent regimen of steroid treatment, we did not observe any
signiﬁcant rise in the IOP that necessitated antiglaucoma
medication, which is assumed to be the result of both the
short duration of treatment and a lower secretion of aqueous
during inﬂammation.
Although several clinical trials have compared different
preserved topical steroid preparations for the treatment of
anterior uveitis,6,17–19 this is the ﬁrst study that evaluates and
FIGURE 4. Mean Schirmer strip wetting length (left) and TBUT (right) with the corresponding error bar depicting the 95%
confidence interval before the treatment and 1 and 2 weeks after the treatment in groups A and B.
FIGURE 3. Mean corneal fluorescein staining scores before the treatment and 1 and 2 weeks after the treatment in groups A and B
(left). Mean subjective discomfort score 1 and 2 weeks after the treatment in groups A and B (right). The corresponding error bars
depict the 95% confidence interval.
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compares the efﬁcacy and safety proﬁle of nonpreserved
methylprednisolone topical treatment. The strengths of this
study include its rather uniform target population and the
use of robust methods for ascertaining clinical outcomes. We
only included patients with pure anterior uveitis (idiopathic and
HLA B27 related) to provide a more uniform population for
comparison. Besides, patients with severe inﬂammation
(including patients with hypopyon or ﬁbrin formation) and
those who did not respond to topical treatment in previous
episodes were excluded because it was deemed unethical to
subject them to a treatment regimen that is most likely not
effective. Moreover, the trial was conducted in 1 center, and
all observations were made by 1 investigator and measurement
devices were similar for all the participants.
As in other clinical studies, there are some limitations
with our study that should be addressed: First, the sample size
is rather small. This is a direct consequence of using restricted
inclusion/exclusion criteria for entering into the study.
Second, more HLA B27 positive patients were allocated in
the prednisolone group than in the methylprednisolone group
(29.4% vs. 18.4%). This may potentially cause a more severe
and more resistant kind of anterior uveitis in the prednisolone-
treated group. However, because we have already excluded
cases with severe inﬂammation at presentation, this difference
may barely affect our results. Finally, our patients were not
masked to the treatment group they had been randomized to
and were aware of which medication they were using.
Because the study only looks at patients with mild-to-moder-
ate disease, patients with severe disease should be evaluated
in future studies, because these are the patients who might
beneﬁt the most from preservative-free treatment.
In conclusion, preservative-free methylprednisolone
1% preparation was shown to be at least as effective as
prednisolone acetonide 1% suspension in resolving the inﬂam-
mation associated with mild-to-moderate noninfectious AAU
with less corneal toxicity and lower subjective discomfort.
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FIGURE 5. The mean IOP and the corresponding error bar
depicting the 95% confidence interval before the treatment
and 1 and 2 weeks after the treatment in groups A and B.
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